ES2582283T3 - Dispositivo médico que comprende aglomerados de nanopartículas magnéticas recubiertas con alcoxisilano - Google Patents

Dispositivo médico que comprende aglomerados de nanopartículas magnéticas recubiertas con alcoxisilano

Info

Publication number
ES2582283T3
ES2582283T3 ES12748166.1T ES12748166T ES2582283T3 ES 2582283 T3 ES2582283 T3 ES 2582283T3 ES 12748166 T ES12748166 T ES 12748166T ES 2582283 T3 ES2582283 T3 ES 2582283T3
Authority
ES
Spain
Prior art keywords
alkoxysilane
agglomerates
medical device
nanoparticles coated
magnetic nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12748166.1T
Other languages
English (en)
Inventor
Norbert WALDÖFNER
Andreas Jordan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magforce AG
Original Assignee
Magforce AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magforce AG filed Critical Magforce AG
Application granted granted Critical
Publication of ES2582283T3 publication Critical patent/ES2582283T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F41/00—Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties
    • H01F41/14—Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for applying magnetic films to substrates
    • H01F41/16—Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for applying magnetic films to substrates the magnetic material being applied in the form of particles, e.g. by serigraphy, to form thick magnetic films or precursors therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Power Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Manufacturing & Machinery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Iron (AREA)
  • Soft Magnetic Materials (AREA)
  • Hard Magnetic Materials (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
  • Powder Metallurgy (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Un dispositivo médico que comprende una suspensión de aglomerados de nanopartículas de metal magnético recubiertas con alcoxisilano, en donde una suspensión acuosa de nanopartículas de metal magnético se incuba con alcoxisilano, caracterizado porque la incubación se realiza esencialmente en ausencia de un solvente orgánico añadido, el alcoxisilano es trialcoxisilano y se añaden 0,3 a 0,6 x 10-3 mol de trialcoxisilano por 0,9 mol de metal.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
Una suspensión 2 M de nanopartículas de óxido de hierro magnético fabricada de acuerdo con el Ejemplo 1 ha sido analizada por TEM. La micrografía resultante se muestra en la Figura 1. En la micrografía, se pueden ver grandes aglomerados de nanopartículas (una nanopartícula individual indicada por una flecha). No se pueden observar nanopartículas individuales dentro del área representada -todas las nanopartículas están unidas entre sí.
7. Especificaciones de la suspensión
Una serie de producción de acuerdo con el ejemplo 1 conduce a las especificaciones físicas/químicas como se muestran en la Tabla 2.
Tabla 2: Especificaciones de una carga representativa
AS1
AS4 AS5
Tamaño de la partícula (promedio z)
89 nm 179,6 180,8 nm
Potencial zeta
53,5 mV 47,8 mV 42,5 mV
Conductividad (25 °C)
2,16 ms/cm 0,90 ms/cm -
pH (25 °C)
5,28 4,38 --
Osmolalidad
0,03 Osmol/kg 0,08 Osmol/kg --
SAR (a 100 kHz, a intensidad del campo dada)
10 W/g Fe (7,5 kA/m) 14 W/g Fe (4 kA/m) 12 W/g Fe (6 kA/m)
Contenido del metal total (Fe)
15% por peso 18% por peso --
Concentración (Fe)
1,99 mol/l 1,70 mol/l 1,88 mol/l
10 8. Reometría de rotación/Medición de la viscosidad
La viscosidad de las muestras de nanopartículas se determinó por servicios de caracterización de materiales Malvern usando reometría de rotación a 20 °C, en donde la viscosidad de cizallamiento (en Pa.s) se determinó en dependencia de la velocidad de cizallamiento (de 7 a 1500/s). Los resultados para preparaciones de nanopartículas de acuerdo con el Ejemplo 1 se muestran en la Figura 2.
15 9. Formación de depósitos de fluidos magnéticos in vivo
Se inyectaron 1x106 células tumorales de la línea celular de carcinoma mamario C3H RSI en la extremidad posterior derecha de los ratones de la cepa C3H-HeN (Harlan Laboratories, Borchen). Una vez que los tumores inducidos tenían un volumen de 0,57-0,85 cm3, los animales fueron asignados al azar (15 animales por grupo) y los tumores de la extremidad posterior derecha fueron inyectados con el fluido magnético del Ejemplo 1 que tiene una concentración
20 de Fe de 112 o 335 mg/ml. El contenido exacto del volumen de inyección se determinó pesando la jeringa de inyección antes y después de la inyección y calculando la diferencia (en promedio, 31 µl ± 5,8 µl).
El contenido de Fe total de tejido/tumor de los ratones se determinó después de 0 o 7 días de medición UV-vis a 565 nm utilizando la prueba de Spektroquant 14761 (Merck, Darmstadt) y un Cary 50 (Agilent Technologies, Santa Clara, Ca, USA) y un espectrómetro Tecan Infinite M 200 (Tecan Group Ltd, Männedorf, Suiza). El contenido de Fe
25 aplicado inicialmente se determinó restando del contenido de Fe total del contenido del tejido/tumor inicial del tejido (determinado midiendo el contenido de Fe de la pata izquierda no inoculada) y la pérdida de fluido magnético durante la inoculación, que fue absorbida por el hisopo utilizado. La recuperación de Fe (promedio de 15 tumores por grupo) se calculó como el contenido total de Fe, dividido por el contenido de Fe aplicado inicialmente.
13
imagen12
imagen13
Thiesen, B. and A. Jordan (2008). Int J Hyperthermia. 24(6): 467-74. Waldoefher, N. and K. Stief (201 1). Magnetic Transducers. US 201 1/0052609.
16

Claims (1)

  1. imagen1
    imagen2
ES12748166.1T 2011-08-10 2012-08-07 Dispositivo médico que comprende aglomerados de nanopartículas magnéticas recubiertas con alcoxisilano Active ES2582283T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161522217P 2011-08-10 2011-08-10
US201161522217P 2011-08-10
PCT/EP2012/003381 WO2013020701A2 (en) 2011-08-10 2012-08-07 Agglomerating magnetic alkoxysilane-coated nanoparticles

Publications (1)

Publication Number Publication Date
ES2582283T3 true ES2582283T3 (es) 2016-09-12

Family

ID=46690467

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12748166.1T Active ES2582283T3 (es) 2011-08-10 2012-08-07 Dispositivo médico que comprende aglomerados de nanopartículas magnéticas recubiertas con alcoxisilano
ES16000350T Active ES2807209T3 (es) 2011-08-10 2012-08-07 Método para fabricar nanopartículas magnéticas aglomerantes recubiertas con alcoxisilano

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16000350T Active ES2807209T3 (es) 2011-08-10 2012-08-07 Método para fabricar nanopartículas magnéticas aglomerantes recubiertas con alcoxisilano

Country Status (21)

Country Link
US (2) US9408912B2 (es)
EP (2) EP2742515B1 (es)
JP (1) JP5844902B2 (es)
KR (1) KR101513841B1 (es)
CN (1) CN104620334B (es)
AU (1) AU2012292554B2 (es)
BR (1) BR112014002726A8 (es)
CA (1) CA2844774C (es)
CL (1) CL2014000298A1 (es)
CO (1) CO6940414A2 (es)
DE (1) DE202012012795U1 (es)
DK (1) DK2742515T3 (es)
ES (2) ES2582283T3 (es)
HK (1) HK1210317A1 (es)
IL (1) IL230799A (es)
MX (1) MX358576B (es)
PL (2) PL3038115T3 (es)
PT (1) PT2742515T (es)
RU (1) RU2622025C2 (es)
WO (1) WO2013020701A2 (es)
ZA (1) ZA201400564B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015188190A1 (en) * 2014-06-06 2015-12-10 The Regents Of The University Of California Sunlight reflecting materials and methods of fabrication
WO2021152136A1 (en) 2020-01-31 2021-08-05 Magforce Ag Paste comprising magnetic alkoxysilane-coated metal containing nanoparticles
DE102020116859A1 (de) 2020-06-26 2021-12-30 Pharma Development Holding Gmbh Liposomen
KR102503870B1 (ko) * 2021-01-08 2023-02-24 한밭대학교 산학협력단 온열치료용 산화철 나노 클러스터 및 이의 제조 방법

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3945945A (en) 1971-05-10 1976-03-23 Norton Company High surface area alumina bodies
US4169912A (en) 1975-10-02 1979-10-02 Dynamit Nobel Aktiengesellschaft Iron oxide magnetic pigments for the production of magnetic coatings
DE2543962A1 (de) 1975-10-02 1977-04-14 Dynamit Nobel Ag Verbesserte eisenoxid-magnetpigmente fuer die herstellung von magnetschichten
CA1254238A (en) 1985-04-30 1989-05-16 Alvin P. Gerk Process for durable sol-gel produced alumina-based ceramics, abrasive grain and abrasive products
US5597531A (en) * 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
FR2618084B1 (fr) 1987-07-15 1989-11-10 Rhone Poulenc Chimie Microspheres magnetisables a base de polysiloxane, leur procede de preparation et leur application en biologie
EP0381742B1 (en) 1988-08-04 1996-06-19 Advanced Magnetics Incorporated Receptor mediated endocytosis type mri contrast agents
EP0451152B1 (en) 1988-10-13 1993-08-25 Tioxide Specialties Limited Ceramic powders
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5462751A (en) 1990-06-22 1995-10-31 The Regeants Of The University Of California Biological and pharmaceutical agents having a nanomeric biodegradable core
DE4026978A1 (de) 1990-08-25 1992-02-27 Bayer Ag Auf traegern angebrachte ein- oder mehrlagige schichtelemente und ihre herstellung
US5616311A (en) 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
JP3389611B2 (ja) 1992-02-28 2003-03-24 戸田工業株式会社 無機物粒子含有樹脂複合球状物粉体
DE4212633A1 (de) 1992-04-15 1993-10-21 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung oberflächenmodifizierter nanoskaliger keramischer Pulver
CA2135769A1 (en) 1992-05-29 1993-12-09 Kent C. Cochrum Coated transplant and method for making same
US5654004A (en) 1992-11-06 1997-08-05 Hisamitsu Pharmaceutical Co., Inc. Oral pharmaceutical preparation releasable in the lower digestive tract
US5401313A (en) 1993-02-10 1995-03-28 Harcros Pigments, Inc. Surface modified particles and method of making the same
US5916539A (en) 1993-03-02 1999-06-29 Silica Gel Ges. M.B.H. Superparamagnetic particles, process for producing the same and their use
JPH06270155A (ja) 1993-03-23 1994-09-27 Sekisui Chem Co Ltd 型内被覆用樹脂組成物
US5547748A (en) 1994-01-14 1996-08-20 Sri International Carbon nanoencapsulates
FR2721615A1 (fr) 1994-06-24 1995-12-29 Rhone Poulenc Chimie Procédé de préparation de particules d'oxyde métallique organophiles.
PL318099A1 (en) 1994-07-07 1997-05-12 Chiron Diagnostics Corp Very fine magnetic particles of metal oxides, methods of obtaining them and their applications
JP3436760B2 (ja) 1994-07-27 2003-08-18 ハーバート ピルグリム 超常磁性粒子
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
US5540959A (en) 1995-02-21 1996-07-30 Howard J. Greenwald Process for preparing a coated substrate
DE19515820A1 (de) 1995-04-29 1996-10-31 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung schwach agglomerierter nanoskaliger Teilchen
JPH09646A (ja) * 1995-06-16 1997-01-07 Toshiba Corp 治療用誘導加熱装置
US6022500A (en) 1995-09-27 2000-02-08 The United States Of America As Represented By The Secretary Of The Army Polymer encapsulation and polymer microsphere composites
US5695900A (en) * 1995-12-21 1997-12-09 Colorado School Of Mines Surface treatment of magnetic particles for use in reprographic processes
US5922403A (en) 1996-03-12 1999-07-13 Tecle; Berhan Method for isolating ultrafine and fine particles
DE19612001A1 (de) 1996-03-18 1997-09-25 Silica Gel Gmbh Adsorptions Te Superparamagnetische Teilchen mit vergrößerter R¶1¶-Relaxivität, Verfahren zur Herstellung und deren Verwendung
DE19614136A1 (de) 1996-04-10 1997-10-16 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung agglomeratfreier nanoskaliger Eisenoxidteilchen mit hydrolysebeständigem Überzug
US5922537A (en) 1996-11-08 1999-07-13 N.o slashed.AB Immunoassay, Inc. Nanoparticles biosensor
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0971692B1 (de) 1997-03-07 2003-03-05 Max-Delbrück-Centrum Für Molekulare Medizin Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung
WO1998053372A1 (de) * 1997-05-23 1998-11-26 Agfa Gevaert Ag Beschichtete partikel
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
DE19912502A1 (de) 1999-03-19 2000-09-21 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung
DE19921088C2 (de) 1999-04-30 2003-08-07 Magforce Applic Gmbh Stent zur Offenhaltung gangartiger Strukturen
DE19940220B4 (de) 1999-08-19 2007-05-03 Magforce Nanotechnologies Ag Medizinisches Präparat zur Behandlung von Arthrose, Arthritis und anderen rheumatischen Gelenkerkrankungen
US6548264B1 (en) 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
US20030092029A1 (en) 2001-06-06 2003-05-15 Lee Josephson Magneitc-nanoparticle conjugates and methods of use
US7731648B2 (en) 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US20040156852A1 (en) 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
DE10153639A1 (de) * 2001-10-31 2003-05-22 Inst Neue Mat Gemein Gmbh Superparamagnetisches Eisenoxid enthaltende Kompositpartikel
DE10261406A1 (de) 2002-12-30 2004-07-15 Sustech Gmbh & Co. Kg Verfahren zur Herstellung oberflächenbeschichteter nanoskaliger Teilchen und von Suspensionen, die diese enthalten
US20040156846A1 (en) 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
DE10331439B3 (de) 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
US20050119725A1 (en) 2003-04-08 2005-06-02 Xingwu Wang Energetically controlled delivery of biologically active material from an implanted medical device
FR2855315B1 (fr) 2003-05-23 2005-08-19 Centre Nat Rech Scient Ferrofluides stables en milieu neutre et ferrofluides modifies obtenus par modification de la surface des particules de ces ferrofluides
US8651113B2 (en) 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7531149B2 (en) 2003-10-14 2009-05-12 The Board Of Trustees Of The University Of Arkansas Synthetic control of metal oxide nanocrystal sizes and shapes
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
DE102004052533A1 (de) 2004-10-15 2006-05-04 Mykhaylyk, Olga, Dr. Magnetische Partikel zur Verwendung in Therapie und Diagnostik
WO2006057467A1 (en) 2004-11-26 2006-06-01 Seoul National University Industry Foundation Method for large-scale production of monodisperse nanoparticles
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
DE102005016873A1 (de) 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
WO2006125452A1 (en) 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
GB0512374D0 (en) 2005-06-17 2005-07-27 Nanosphere Ltd Coated microspheres
DE102005039579B4 (de) * 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US20070269380A1 (en) 2005-10-11 2007-11-22 Washington, University Of Methotrexate-modified nanoparticles and related methods
DE102005059751A1 (de) 2005-12-09 2007-06-14 Ferropharm Gmbh Forschungslabor Wässrige Dispersion von superparamagnetischen Eindomänenteilchen, deren Herstellung und Verwendung zur Diagnose und Therapie
JP2008019202A (ja) * 2006-07-12 2008-01-31 Koichi Jinbo メラノーマ標的温熱免疫療法治療剤
WO2008014623A1 (fr) 2006-07-31 2008-02-07 Ecole Polytechnique Federale De Lausanne (Epfl) Nanoparticules a noyau metallique recouvert de silice
TWI321133B (en) 2006-08-01 2010-03-01 Univ Kaohsiung Medical Folate-receptor-targeting iron oxide nanoparticles coated with poly(ethylene glycol)
RU2373957C2 (ru) * 2006-10-13 2009-11-27 Александр Метталинович Тишин Носитель для лекарственных средств и биологически активных веществ для лечения и диагностики и применение его для создания лекарственных средств и способа регулируемой управляемой доставки лекарственного средства или биологически активного вещества с регулируемой десорбцией его
EP1935436A1 (en) 2006-12-12 2008-06-25 Dublin City University Nanoparticle clusters and methods for forming same
JP5057208B2 (ja) * 2006-12-20 2012-10-24 株式会社豊田中央研究所 磁性材料の製造方法
US20110104073A1 (en) 2007-01-18 2011-05-05 Qi Zeng Iron/Iron Oxide Nanoparticle and Use Thereof
EP1952919B1 (en) 2007-02-02 2013-04-24 FUJIFILM Corporation Magnetic nanoparticles and aqueous colloid composition containing the same
EP2242805A1 (en) 2008-01-04 2010-10-27 Sparkxis B.V. Surface modification of metal oxide nanoparticles
DE102008003615A1 (de) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
US20100284924A1 (en) 2008-01-23 2010-11-11 The Regents Of The University Of California Nano-devices having impellers for capture and release of molecules
DE102008008522A1 (de) * 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
US20090226376A1 (en) 2008-03-05 2009-09-10 General Electric Company Novel Mixed Ligand Core/Shell Iron Oxide Nanoparticles for Inflammation Imaging
WO2010062615A1 (en) 2008-10-27 2010-06-03 Board Of Trustees Of The University Of Arkansas Metallic nanoparticles with coated shells and applications of same
GB2472446A (en) 2009-08-07 2011-02-09 Ct Fuer Angewandte Nanotechnologie Metal oxide particles coated with polyethylene glycol and their synthesis
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
EP2383374A1 (en) 2010-04-29 2011-11-02 BASF Corporation Nano-particles containing carbon and a ferromagnetic metal or alloy
JP2013526616A (ja) 2010-05-26 2013-06-24 ザ ジェネラル ホスピタル コーポレイション 磁性ナノ粒子
CN102971014A (zh) 2010-06-29 2013-03-13 皇家飞利浦电子股份有限公司 用于磁性粒子成像(mpi)的高性能铁氧化物粒子示踪剂的合成
TW201247225A (en) 2011-05-17 2012-12-01 Univ Nat Chiao Tung Drug carrier with thermal sensitivity, manufacturing method thereof, and use of the same as NMR contrast agent
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines

Also Published As

Publication number Publication date
IL230799A (en) 2017-12-31
BR112014002726A8 (pt) 2017-06-20
JP2014532291A (ja) 2014-12-04
ES2807209T3 (es) 2021-02-22
EP3038115B1 (en) 2020-05-06
ZA201400564B (en) 2015-12-23
CL2014000298A1 (es) 2014-07-18
PL3038115T3 (pl) 2020-11-02
CA2844774A1 (en) 2013-02-14
RU2622025C2 (ru) 2017-06-08
AU2012292554B2 (en) 2014-10-30
PT2742515T (pt) 2016-07-14
RU2014109015A (ru) 2015-09-20
BR112014002726A2 (pt) 2017-06-13
EP2742515A2 (en) 2014-06-18
KR101513841B1 (ko) 2015-04-24
US9962442B2 (en) 2018-05-08
CN104620334A (zh) 2015-05-13
DK2742515T3 (en) 2016-06-13
WO2013020701A3 (en) 2013-04-04
MX358576B (es) 2018-08-27
DE202012012795U1 (de) 2013-11-21
CN104620334B (zh) 2016-10-26
EP3038115A1 (en) 2016-06-29
CO6940414A2 (es) 2014-05-09
PL2742515T3 (pl) 2017-03-31
US20140154324A1 (en) 2014-06-05
JP5844902B2 (ja) 2016-01-20
EP2742515B1 (en) 2016-04-13
US20160367673A1 (en) 2016-12-22
WO2013020701A2 (en) 2013-02-14
AU2012292554A1 (en) 2013-05-02
KR20140037290A (ko) 2014-03-26
US9408912B2 (en) 2016-08-09
IL230799A0 (en) 2014-03-31
CA2844774C (en) 2019-08-27
HK1210317A1 (zh) 2016-04-15
MX2014001186A (es) 2014-05-13

Similar Documents

Publication Publication Date Title
Chong et al. The in vitro and in vivo toxicity of graphene quantum dots
Garanina et al. Temperature-controlled magnetic nanoparticles hyperthermia inhibits primary tumor growth and metastases dissemination
Liu et al. Thermoresponsive nanogel‐encapsulated PEDOT and HSP70 inhibitor for improving the depth of the photothermal therapeutic effect
Alphandéry et al. Development of non-pyrogenic magnetosome minerals coated with poly-l-lysine leading to full disappearance of intracranial U87-Luc glioblastoma in 100% of treated mice using magnetic hyperthermia
Alphandéry et al. Preparation of chains of magnetosomes, isolated from Magnetospirillum magneticum strain AMB-1 magnetotactic bacteria, yielding efficient treatment of tumors using magnetic hyperthermia
Alphandéry Applications of magnetosomes synthesized by magnetotactic bacteria in medicine
Pi et al. Selenium nanoparticles induced membrane bio-mechanical property changes in MCF-7 cells by disturbing membrane molecules and F-actin
Bai et al. Inductive heating property of graphene oxide–Fe3O4 nanoparticles hybrid in an AC magnetic field for localized hyperthermia
Céspedes et al. Bacterially synthesized ferrite nanoparticles for magnetic hyperthermia applications
Wang et al. Challenge in understanding size and shape dependent toxicity of gold nanomaterials in human skin keratinocytes
Yan et al. The use of polyethylenimine-modified graphene oxide as a nanocarrier for transferring hydrophobic nanocrystals into water to produce water-dispersible hybrids for use in drug delivery
Xu et al. An intelligent nanoplatform for imaging-guided photodynamic/photothermal/chemo-therapy based on upconversion nanoparticles and CuS integrated black phosphorus
Shi et al. Engineered multifunctional nanocarriers for cancer diagnosis and therapeutics
Patil et al. In vitro hyperthermia with improved colloidal stability and enhanced SAR of magnetic core/shell nanostructures
ES2582283T3 (es) Dispositivo médico que comprende aglomerados de nanopartículas magnéticas recubiertas con alcoxisilano
Tian et al. Near Infrared‐Triggered Theranostic Nanoplatform with Controlled Release of HSP90 Inhibitor for Synergistic Mild Photothermal and Enhanced Nanocatalytic Therapy with Hypoxia Relief
Chen et al. Azo-functionalized Fe 3 O 4 nanoparticles: a near-infrared light triggered drug delivery system for combined therapy of cancer with low toxicity
Zheng et al. Preparation of AS1411 aptamer modified Mn-MoS2 QDs for targeted MR imaging and fluorescence labelling of renal cell carcinoma
Ali et al. Graphene oxide/zinc ferrite nanocomposite loaded with doxorubicin as a potential theranostic mediu in cancer therapy and magnetic resonance imaging
Ding et al. Redox-responsive dextran based theranostic nanoparticles for near-infrared/magnetic resonance imaging and magnetically targeted photodynamic therapy
Nebu et al. Erlotinib conjugated gold nanocluster enveloped magnetic iron oxide nanoparticles–A targeted probe for imaging pancreatic cancer cells
Yan et al. Neoadjuvant nano-photothermal therapy used before operation effectively assists in surgery for breast cancer
Chen et al. Laser-assisted in situ synthesis of graphene-based magnetic-responsive hybrids for multimodal imaging-guided chemo/photothermal synergistic therapy
Pham et al. Magnetic inductive heating of organs of mouse models treated by copolymer coated Fe3O4 nanoparticles
Foroutan et al. Intraperitoneal injection of graphene oxide nanoparticle accelerates stem cell therapy effects on acute kidney injury